Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 31, 2024
Product Development

Clinical Report: BioNTech claims mRNA cancer vaccine success

Plus data from NewAmsterdam, Pfizer, Calliditas, Ventyx and Viking
BioCentury | May 30, 2024
Product Development

Renal therapies get disease-specific

Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | May 28, 2024
Deals

Asahi Kasei rides renal momentum with $1.1B Calliditas takeout

Deal gives Japanese pharma Tarpeyo, first drug approved to treat IgA nephropathy 
BioCentury | May 7, 2024
Product Development

Clinical report: Calliditas data provide mixed support for anti-fibrotic cancer mechanism

Plus: J&J aiming to replace bladder cancer surgery with TAR-210, and updates from Merck, GlycoMimetics, EyePoint and more
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

A look at new and emerging targets at AACR 2019 and their mechanisms
Items per page:
1 - 10 of 31